Latest Commercial Expansion News

Page 1 of 12
Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.
Ada Torres
Ada Torres
19 Mar 2026
TZ Limited has completed a A$1.5 million capital raise at a premium, appointed David Sampaklis as Group CEO with significant shareholding, and repaid A$1 million of debt, positioning itself for growth in data centre security.
Sophie Babbage
Sophie Babbage
12 Mar 2026
Straker Ltd announces a pivotal leadership shift with the appointment of David Sowerby and Indiver Nagpal as Co-CEOs, marking a new era focused on commercial expansion and AI innovation. Founder Grant Straker transitions to a strategic board role to steer the company’s AI future.
Sophie Babbage
Sophie Babbage
4 Mar 2026
Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.
Sophie Babbage
Sophie Babbage
27 Feb 2026
4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.
Ada Torres
Ada Torres
27 Feb 2026
ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.
Ada Torres
Ada Torres
26 Feb 2026
First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.
Maxwell Dee
Maxwell Dee
25 Feb 2026
Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.
Ada Torres
Ada Torres
25 Feb 2026
Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.
Ada Torres
Ada Torres
25 Feb 2026
OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.
Ada Torres
Ada Torres
24 Feb 2026
Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.
Ada Torres
Ada Torres
20 Feb 2026
Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.
Ada Torres
Ada Torres
18 Feb 2026